Search

Displaying results 2521 - 2530 of 4859 in total
  1. Drug

    Rusfertide

    go.drugbank.com/drugs/DB17724
    ApprovedInvestigational

    [L64113] It is the first hepcidin mimetic approved for polycythemia vera.[L64113] … [L64098] It is a synthetic cyclic peptide that blocks the iron transporter ferroportin, reducing the availability of iron for red blood cell production and lowering hematocrit.

  2. Drug

    Buclizine

    go.drugbank.com/drugs/DB00354
    Approved

    It was manufactured by Stuart Pharms and initially approved by the FDA in 1957. … [L6217] Following this, it was touted to be effective as an appetite stimulant in children when administered in the syrup form, however, this indication has not been validated.

  3. Drug

    Brepocitinib

    go.drugbank.com/drugs/DB15003
    ApprovedInvestigational

    [L64097] It inhibits TYK2- and JAK1-mediated cytokine signaling, blocking phosphorylation of signal transducers and activators of transcription (STATs) that regulate immune cell function. … [L64097] The FDA approved brepocitinib on August 27, 2026 for the treatment of dermatomyositis in adult patients, making it the first targeted oral therapy approved for the condition.[L64115]

  4. Drug

    Deoxycholic acid

    go.drugbank.com/drugs/DB03619
    ApprovedInvestigational

    Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that … It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical

  5. Drug

    Talmapimod

    go.drugbank.com/drugs/DB05412
    Investigational

    It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.

  6. Drug

    Inotuzumab ozogamicin

    go.drugbank.com/drugs/DB05889
    ApprovedInvestigational

    Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide. The antibody por...

  7. Drug

    SP1049C

    go.drugbank.com/drugs/DB04978
    Experimental

    [A260416] It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review.

  8. Drug

    Lancovutide

    go.drugbank.com/drugs/DB05029
    Investigational

    It belongs to the lantibiotics. Lantibiotics are bacteriocins that are characterized by the presence of a high proportion of unusual amino acids.

  9. Drug

    Agkistrodon piscivorus antivenin

    go.drugbank.com/drugs/DB13894
    Approved

    It is intravenously (IV) administered to limit/prevent systemic toxicity [FDA label]. … The cottonmouth, Agkistrodon piscivorus, is a large, venomous snake in the pit viper subfamily (Crotalinae).

  10. Drug

    Cyclandelate

    go.drugbank.com/drugs/DB04838
    ApprovedWithdrawn

    It may cause gastrointestinal distress and tachycardia. Cyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries.